Straits Times Index
3,278.00 -15.13 (-0.46%) Nikkei
37,628.48 -831.60 (-2.16%) Hang Seng
17,235.72 +34.45 (+0.20%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,342.71 -2,289.19 (-3.44%) CMC Crypto 200
1,390.67 +8.10 (+0.59%)
Oxurion NV (0G99.L)
| Previous close | 0.0001 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 8,955 |
| Market cap | 38 |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7590 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswirePublication Annual Report – Annual Shareholders' Meeting
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. On this day as well, the Company has convened its Annual Shareholders' Meeting
- GlobeNewswire
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Leuven, BELGIUM – April 11, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received two transparency notifications as follows: Oxurion received a first transparency notification on April 10, 2024, from Atlas Special Opportunities, LLC indicating that as of April 1, 2024, it held
- GlobeNewswire
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program. On April 10, 2024, the Company issued the Eleventh Tranche consisting of 18 convertible bonds, for an aggregate amount of EUR 450,000. T
